By Adria Calatayud
Novartis said it agreed to buy Excellergy for up to $2 billion, bulking up its immunology portfolio with a biotech company that specializes in treatments for food allergy and other diseases.
The Swiss pharmaceutical company said Friday that the deal for privately-held Excellergy will add a drug candidate in early-stage trials with potential to complement its existing allergy portfolio.
The deal follows Novartis's agreement last week to buy a breast-cancer drug candidate from Synnovation Therapeutics for up to $3 billion, as the company turns to dealmaking to fill its pipeline and offset patent expirations.
Novartis said the acquisition builds on its long-standing presence in allergic disease.
The lead drug in Excellergy's portfolio is a so-called anti-IgE antibody. Novartis said the drug offers a differentiated mechanism that, if confirmed clinically, could support earlier symptom relief, stronger disease control and more convenient dosing across food allergy, hives, allergic asthma and other diseases.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
03-27-26 0236ET
